Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial.

Lotfollah DavoodiSeyed Mohammad AbediEbrahim SalehifarReza Alizadeh-NavaeiHamed RouhanizadehGhasemali KhorasaniSeyed Jalal Hosseinimehr

Published in: International journal of clinical practice (2020)

This trial suggests that FBX is as an alternative treatment to HCQ for COVID-19 infection and may be considered in patients with a contraindication or precaution to HCQ.

Keyphrases

clinical trial
phase ii
study protocol
coronavirus disease
phase iii
sars cov
pulmonary embolism
open label
randomized controlled trial
stem cells